Humacyte (NASDAQ:HUMA) Price Target Lowered to $1.00 at Benchmark

Humacyte (NASDAQ:HUMA) had its price objective dropped by analysts at Benchmark from $2.00 to $1.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “speculative buy” rating on the stock. Benchmark’s price target points to a potential upside of 51.06% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. BTIG Research restated a “buy” rating and issued a $2.00 target price on shares of Humacyte in a research note on Wednesday. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research note on Tuesday, April 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a report on Wednesday, July 8th. TD Cowen reduced their target price on Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a report on Wednesday, June 17th. Finally, HC Wainwright lifted their target price on Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Humacyte has a consensus rating of “Moderate Buy” and an average target price of $6.11.

Humacyte Stock Performance

Humacyte stock opened at $0.66 on Thursday. Humacyte has a 52 week low of $0.55 and a 52 week high of $2.55. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46. The stock has a market cap of $146.98 million, a P/E ratio of -1.18 and a beta of 2.53. The stock has a 50 day moving average of $0.81 and a 200-day moving average of $0.91.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). The company had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.12 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%. On average, analysts expect that Humacyte will post -0.34 EPS for the current fiscal year.

Insider Activity at Humacyte

In other Humacyte news, insider Shamik J. Parikh sold 45,887 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the sale, the insider directly owned 272,713 shares in the company, valued at approximately $245,441.70. This trade represents a 14.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius purchased 56,818 shares of Humacyte stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average cost of $0.88 per share, with a total value of $49,999.84. Following the acquisition, the director owned 148,025 shares of the company’s stock, valued at approximately $130,262. This trade represents a 62.30% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 3.10% of the company’s stock.

Institutional Trading of Humacyte

Several hedge funds have recently bought and sold shares of HUMA. R Squared Ltd bought a new position in Humacyte in the 4th quarter worth about $25,000. Atom Investors LP acquired a new position in shares of Humacyte during the fourth quarter worth approximately $25,000. Prudential Financial Inc. acquired a new position in shares of Humacyte during the second quarter valued at $28,000. Financial Advisors Network Inc. acquired a new position in Humacyte during the 2nd quarter valued at about $28,000. Finally, Equitable Holdings Inc. bought a new stake in shares of Humacyte during the 3rd quarter worth about $29,000. 44.71% of the stock is currently owned by institutional investors.

Key Headlines Impacting Humacyte

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: Strong Phase 3 dialysis results: In the V012 trial of female dialysis patients, Humacyte’s acellular tissue-engineered vessel (ATEV) outperformed traditional AV fistula access. Patients receiving ATEV had an average of 91 additional catheter-free days, while infection rates were 6 versus 23 per 100 patient-years. The data met the primary efficacy endpoint and supports a planned supplemental BLA filing in the second half of 2026. Humacyte Reports Stronger Phase 3 Dialysis Results in Women
• Positive Sentiment: Potential regulatory and commercial milestones: Management expects the FDA to issue a PDUFA decision around May 2027, with a possible dialysis-access launch by the end of the second quarter of 2027. The FDA also accepted Humacyte’s IND for a first-in-human study of its coronary tissue-engineered vessel, with a Phase 2a CABG study planned for the third quarter of 2026. Humacyte Targets November sBLA Filing
• Positive Sentiment: Early Symvess adoption improved: Second-quarter product sales rose to $0.4 million from $0.1 million a year earlier. Humacyte is rebuilding its commercial organization and adding hospital pricing, education and market-access initiatives to increase utilization. Humacyte Second-Quarter Financial Results
• Positive Sentiment: Additional funding: Humacyte raised $57.5 million through a public offering, providing capital for commercialization, regulatory filings and pipeline development.
• Neutral Sentiment: Cash runway remains a key focus: The company reported $80.3 million in cash, cash equivalents and restricted cash at June 30, while cost reductions are expected to save approximately $14.3 million during 2026.
• Negative Sentiment: Quarterly results missed expectations: Humacyte reported a second-quarter loss of $0.16 per share versus the consensus loss estimate of $0.11, while revenue of $0.41 million fell well short of the $1.12 million estimate. Humacyte Reports Q2 Loss and Misses Revenue Estimates
• Negative Sentiment: Large losses and weak near-term profitability: Net loss was $36.8 million, and cost of goods sold increased to $1.2 million despite limited revenue. The public offering also increases the risk of shareholder dilution.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.